

Table S2. Overlap of samples from the current genome-wide association study (GWAS) and the previous GWAS [1] reporting association between 6p21.32 and follicular lymphoma (FL) risk.

<i>Current GWAS Study</i>			<i>Previous GWAS Study⁶</i>			Comments
Stage	Study	Samples cases/controls	Stage	Study	Samples cases/controls	
FL Stage 1	SCALE1	379/791	FL Stage 1	SF1	213/750	The current and the previous GWAS studies were conducted in two different cohorts (SCALE1 and SF1, respectively), providing different top-associated SNPs that were taken forward to Stage 2 ^a
FL Stage 2	SF1	213/750	FL Stage 2	SCALE	379/791	The previous GWAS study used 38 SNPs from the current SCALE1 in Stage 2 validation
FL Stage 3	NCI-SEER	157/501	FL Stage 3	NCI-SEER	153/482	The current GWAS study used 39 SNPs from the previous SF1 in Stage 2 validation ^a
	NSW	161/398		NSW	141/369	
	Yale	98/460		Yale	98/460	
	BC	174/610		BC	174/610	
	Mayo	246/1233		-	-	
FL Stages 1-3	Combined	1428/4743	FL Stages 1-3	Combined	1158/3462	75% of participants in the current FL GWAS study were included in the previous study
Evaluation other subtypes	SCALE2	1869/2018	DLBCL, CLL/SLL Stage 3	-	-	
	NCI-SEER	468		NCI-SEER	219	
	NSW	261		NSW	118	
	Yale	300		Yale	38	
	BC	451		BC	200	
	Mayo	843		-	-	
	SF2	257	DLBCL Stage 1	SF1	257	
	Combined	4449/2018		Combined	832	13% of participants in the current evaluation of FL-associated SNPs among other subtypes were included in the previous study
Grand total		5877/6761			2090/3462	Overall, 44 % of participants in the current study were included in the previous study

^ars10484561 was the only SNP that ranked among the top 40 in both the current and the previous FL GWAS studies, only adjusted results for rs10484561 are presented in the current study. Abbreviations: SCALE: Scandinavian lymphoma etiology, SF: San Francisco, NCI-SEER: National Cancer Institute, NSW: New South Wales, Yale: Yale University, BC: British Columbia, Mayo: Mayo Clinic.